You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Adrenergic alpha-2 Receptor Agonists

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Delirium, Cognitive Decline, Frailty Trial in Bergen, Oslo, Trondheim (Dexmedetomidine, Clonidine, Natriumchlorid)

Recruiting
  • Delirium
  • +2 more
  • Bergen, Norway
  • +3 more
Apr 25, 2022

Glaucoma, Suspect, Aberration, Corneal Wavefront Trial in Banha (Low dosage selective alpha-2 receptor agonists topical eyedrop,

Recruiting
  • Glaucoma, Suspect
  • Aberration, Corneal Wavefront
  • Low dosage selective alpha-2 receptor agonists topical eyedrop
  • High dosage selective alpha-2 receptor agonists topical eyedrop
  • Banhā, QA, Egypt
    Ahmed Abdelshafy
Jan 2, 2023

Glucagon-like Peptide-1 Receptor Agonists According to Type 2

Recruiting
  • Diabetes Mellitus, Type 2
  • GLP-1 receptor agonist
  • Bari, Italy
    Azienda Ospedaliero-Universitaria Policlinico Bari
Nov 4, 2023

Adverse Effect Trial (Alpha-Agonist, a-adrenergic receptor agonist)

Not yet recruiting
  • Adverse Effect
  • (no location specified)
Nov 28, 2023

Adverse Effect Trial (Alpha-Agonist, a-adrenergic receptor agonist)

Not yet recruiting
  • Adverse Effect
  • (no location specified)
Nov 28, 2023

Adverse Effect Trial (Alpha-Agonist, a-adrenergic receptor agonist)

Not yet recruiting
  • Adverse Effect
  • (no location specified)
Nov 28, 2023

Adverse Effect Trial (Alpha-Agonist, a-adrenergic receptor agonist)

Not yet recruiting
  • Adverse Effect
  • (no location specified)
Nov 28, 2023

Outcome Trial (Alpha-Agonist, a-adrenergic receptor agonist)

Not yet recruiting
  • Outcome
  • (no location specified)
Nov 28, 2023

Outcome Trial (Alpha-Agonist, a-adrenergic receptor agonist)

Not yet recruiting
  • Outcome
  • (no location specified)
Nov 28, 2023

Adverse Effect Trial (Alpha-Agonist, a-adrenergic receptor agonist)

Not yet recruiting
  • Adverse Effect
  • (no location specified)
Nov 28, 2023

Adverse Effect Trial (Alpha-Agonist, a-adrenergic receptor agonist)

Not yet recruiting
  • Adverse Effect
  • (no location specified)
Nov 28, 2023

Type 2 Diabetes Trial in Lancaster (Exenatide Injection, Saline injection)

Terminated
  • Type 2 Diabetes
  • Exenatide Injection
  • Saline injection
  • Lancaster, Pennsylvania
    Amish Research Clinic
Mar 6, 2023

Diabetes Trial in Nanjing (Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc)

Recruiting
  • Diabetes
  • Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc
  • Nanjing, China
    Nanjing First Hospital, Nanjing Medical Univesity
Aug 6, 2023

Glucagon-like Peptide 1 Receptor Agonists and Mental Health

Not yet recruiting
  • Diabetes Mellitus
  • +2 more
  • GLP-1 receptor agonist
  • (no location specified)
Aug 4, 2022

Osteoporosis, Postmenopausal, Diabetes, Type 2 Trial in Jackson (GLP-1 receptor agonist)

Recruiting
  • Osteoporosis, Postmenopausal
  • Diabetes Mellitus, Type 2
  • GLP-1 receptor agonist
  • Jackson, Mississippi
    University of Mississippi Medical Center
Aug 5, 2022

A Pan-European Post-Authorisation Safety Study: Risk of

Not yet recruiting
  • Pancreatic Cancer
  • Exenatide
  • Non-GLP-1 RA based glucose lowering drugs
  • (no location specified)
Dec 21, 2022

Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or

Completed
  • Alcohol Withdrawal Syndrome
  • BZDP-Sparing Protocol
  • BZDP-Based Protocol
  • Stanford, California
    Stanford Hospital and Clinics
Jun 24, 2022

Aging, Diabetes, Type 2, PreDiabetes Trial in San Antonio (Semaglutide Injectable Product, Lifestyle Counseling)

Recruiting
  • Aging
  • +3 more
  • Semaglutide Injectable Product
  • Lifestyle Counseling
  • San Antonio, Texas
    UT Health San Antonio
Apr 3, 2023

Therapeutic Drug Use for CKD Patients

Active, not recruiting
  • Chronic Kidney Disease
  • angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker
  • Jinan, Shandong, China
    Xiao Li，MD
Apr 18, 2023

GLP-1RAs) and SGLT2is Combination Therapy and MACEs in Type 2

Recruiting
  • Diabetes Mellitus, Type 2
  • Myocardial Infarction
  • PCI
  • Naples, Italy
    Celestino Sardu
Aug 31, 2023

GLP-1 Receptor Agonists on Efficacy and Persistence, Adherence

Completed
  • Type 2 Diabetes
  • Obesity
  • Valencia, Spain
    INCLIVA
Sep 6, 2022

SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS ,

Active, not recruiting
  • Weight Loss
  • +3 more
  • GLP-1 receptor agonist
  • Culleredo, A Coruña, Spain
  • +10 more
Jan 13, 2023

Type 2 Diabetes, Obesity Trial in Sherbrooke (drug, other, diagnostic test, procedure)

Recruiting
  • Type 2 Diabetes
  • Obesity
  • Formoterol Fumarate 12 micrograms Inhalation Powder
  • +8 more
  • Sherbrooke, Quebec, Canada
    Centre de recherche du CHUS
Sep 22, 2022

Based on Data From German Sick Funds That Looks at Costs of

Completed
  • Diabetes Mellitus, Type 2
  • Ingelheim am Rhein, Germany
    Boehringer Ingelheim
Jan 18, 2022

Type 2 Diabetes Trial in Xuzhou (GLP-1 receptor agonist)

Recruiting
  • Type 2 Diabetes Mellitus
  • GLP-1 receptor agonist
  • Xuzhou, Jiangsu, China
    Department of Endocrinology
Apr 16, 2022